UPAR Targeting to Enable CAR T Cell Therapies to Treat Solid Cancers

Key Takeaways

• uPAR overexpressed in majority of solid cancers
• uPAR CAR T kills tumor and stromal cells
• Cisplatin increases uPAR, enhancing CAR T efficacy
• Treated mice showed lasting remission and tumor resistance
• Strategy targets cell state, not specific lineage

Pulse Analysis

CAR T cell therapy has revolutionized treatment for leukemias and lymphomas, yet solid tumors have remained elusive due to a hostile microenvironment and heterogeneous antigen expression. The urokinase plasminogen activator receptor (uPAR) emerges as a promising universal marker because it is minimally present in healthy tissue but highly up‑regulated on aggressive cancer cells and the surrounding fibro‑vascular niche. Targeting uPAR therefore allows engineered T cells to recognize both malignant cells and the supportive stroma that fuels tumor growth, addressing a critical gap in current immunotherapy designs.

In mouse models, uPAR‑directed CAR T cells demonstrated potent cytotoxicity across diverse cancer types, with especially striking results in ovarian cancer where metastases were completely cleared. The efficacy was amplified when cisplatin, a DNA‑damaging chemotherapy, was administered beforehand; the drug induced senescence‑associated uPAR expression, rendering tumor cells more visible to the CAR T cells. Importantly, mice that achieved tumor eradication maintained functional CAR T populations and rejected subsequent tumor implantation, suggesting the therapy can induce durable immune memory beyond the initial treatment window.

For biotech investors and pharmaceutical developers, these findings signal a viable route to expand the lucrative CAR T market beyond hematologic indications. While manufacturing costs and safety profiling remain challenges, the ability to target a broadly expressed, disease‑specific surface protein could streamline regulatory pathways and accelerate multi‑cancer trial designs. As the field moves toward combination regimens and off‑the‑shelf cell products, uPAR‑targeted CAR T therapy positions itself as a strategic asset for companies seeking to capture the next wave of solid‑tumor immunotherapies.